Japanese Foundation for Cancer Research

Koninklijke Philips Corporation N.v.

Olympus Corporation

Kyoto University

Educational Foundation Jichi Medical University

Finggal Link Co., Ltd

Kengo Takeuchi

Yuki Togashi

Seiji Sakata

Yuichi Ishikawa

Naoya Fujita

Ryohei Katayama

Takuya Sato

Hiroyuki Mano

Tatsuki Yamada

Satoko Baba

Masayuki Hayashi

Manabu Soda

Sayuri Nakamura

Seishi Ogawa

Keisuke Kataoka

Eirin Sai

Naoko Tsuyama

A laboratory information system (LIS) is linked with a whole slide image (WSI) management system to build a pathology image management system that can efficiently manage and utilize a digitized pathology image. A scan notification notifying that an image of a glass slide is scanned by a scanner is delivered to the LIS from the WSI management system to form a WSI link in the LIS, so that the LIS is linked with the WSI management system. By linking two systems with each other can eliminate the problem of mixing up specimens, for example, and hence, a pathologist can easily grasp the status of a pathology sample for which the pathologist is responsible.

Pathology image management system

It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

Fusions and method for detecting same

A polynucleotide, which is a novel causative gene for cancer, is elucidated, and, based on this finding, provided are a method for detecting the polynucleotide, or a polypeptide encoded by the polynucleotide; a kit and a primer set for the detection; a method for screening an inhibitor of the polypeptide; and a pharmaceutical composition for treating a cancer containing the inhibitor. In the detection method of the present invention, an NTRK3 fusion protein, or a fusion gene encoding the fusion protein, or an ETV6 fusion protein, or a fusion gene encoding the fusion protein, in a sample derived from the digestive system obtained from a subject, is detected.

Detection method for NTRK3 fusion

An object of the present invention is to provide an effective method of predicting an effect of treatment by a PD-1/PD-L1 blockade, which is a method of predicting whether or not PD-1/PD-L1 blockade is effective for treatment of a subject suffering from a malignant tumor, which comprises detecting abnormality of genome relating to effectiveness of the PD-1/PD-L1 blockade in a tumor cell taken from the subject and evaluating the PD-1/PD-L1 blockade as useful for the treatment of the subject when there is the abnormality.

Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index

A polynucleotide, which is a novel causative gene for cancer, is elucidated, and, based on this finding, provided are a method for detecting the polynucleotide, or a polypeptide encoded by the polynucleotide; a kit and a primer set for the detection; a method for screening an inhibitor of the polypeptide; and a pharmaceutical composition for treating a cancer containing the inhibitor. In the detection method of the present invention, an FGFR3 fusion protein, or a fusion gene encoding the fusion protein, or a TACC3 fusion protein, or a fusion gene encoding the fusion protein, is detected in a sample derived from female genitalia obtained from a subject.

Method for detecting an FGFR3/TACC3 fusion protein, or encoding gene thereof

Polynucleotides which are novel causative genes for cancer are elucidated, and a detection method of the polynucleotides or polypeptides encoded by the polynucleotides, and a kit and a primer set for detection are provided, based on the knowledge gained by the elucidation. In the detection method, a fusion gene comprising part of an SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 gene and part of a ROS1 gene, or a fusion protein encoded by the fusion gene is detected. The primer set or the detection kit comprises a sense primer designed based on a portion encoding SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 and an antisense primer designed based on a portion encoding ROS1.

Detection method for novel ROS1 fusions

A microscope system includes an acquisition unit that obtains a specimen image acquired by capturing the specimen stained by an element identification dye that visualizes a predetermined cell constituent element and a molecule target dye that visualizes a predetermined target molecule by using a microscope; a dye amount unit that obtains dye amounts of the element identification dye and the molecule target dye that stain corresponding positions on the specimen for each pixel of the image; an element area identification unit that identifies an area of the cell constituent element based on the dye amount of the element identification dye; a condition setting unit that sets the presence or absence of the predetermined target molecule on the cell constituent element as a condition; and an extraction unit that extracts an area of a target portion that satisfies the condition based on the dye amount of the molecule target dye.

Microscope cell staining observation system, method, and computer program product

Growing community of inventors

Tokyo, Japan

Kengo Takeuchi